J&J's Kenvue valued at $48 billion after shares jump in market debut
Reuters
Published May 04, 2023 10:11AM ET
Updated May 04, 2023 01:17PM ET
(Reuters) -Johnson & Johnson's consumer health spinoff Kenvue Inc rose 16% and fetched a valuation of about $48 billion in its market debut on Thursday, marking the biggest U.S. initial public offering since 2021.
Shares of the Listerine mouthwash maker debuted at $25.53 each, compared with their offer price of $22 apiece.
J&J (NYSE:JNJ) sold 172.8 million shares of the business in an upsized offering to raise $3.8 billion, and said it will continue to own a stake of about 91% in Kenvue.
Kenvue's stellar debut comes as good news for hopefuls waiting for market conditions to improve before moving ahead with their listings, in an IPO market that has largely been frozen over the past year due to stock-market volatility and economic uncertainty.
"Investors are very valuation sensitive now, and Kenvue is easier to pin a value on than, say, a tech unicorn. It has mature brands ... consumers should continue to buy these brands even in a recession," Matt Kennedy, senior strategist at Renaissance Capital, said.
Kenvue marks the largest offering to launch since electric-vehicle maker Rivian Automotive Inc listed its shares on the Nasdaq in late 2021.
IPOs in the U.S., excluding SPACs, raised a record $154.07 billion in 2021, which fell to $8.63 billion last year as markets reeled under macroeconomic uncertainty, data from Dealogic showed.
U.S. IPOs, excluding listings for SPACs, are down about 22% to a total of just $2.35 billion from the start of 2023 till May 3.
J&J shares fell marginally to $162 after Kenvue, whose products have long been the face of the company, debuted.
Kenvue's listing comes a year after J&J's British rival GSK also completed the spinoff of its consumer health business. Shares of the London-listed arm called Haleon have risen 9.4% from their closing price on debut day in July 2022.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.